INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Status:
Withdrawn
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, open-label phase Ib study aimed at determining a
recommended phase II dose of INCB053914 and pomalidomide with dexamethasone. The trial will
follow a 3 + 3 phase I dose-escalation design.